A subcutaneous insulin pharmacokinetic model for computer simulation in a diabetes decision support role: Validation and simulation

Journal of Diabetes Science and Technology

Volumn 2, Issue 4, 2008, Pages 672-680

  Wong, Jason ^a   Chase, J Geoffrey ^a   Hann, Christopher E ^a   Shaw, Geoffrey M ^b   Lotz, Thomas F ^a   Lin, Jessica ^a   Le Compte, Aaron J ^a  

^a UNIVERSITY OF CANTERBURY   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Blood glucose; Compartmental models; Decision support; Diabetes; Hyperglycemia; Insulin; Simulation; Subcutaneous injection

Indexed keywords

EID: 77951019655     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229680800200418     Document Type: Article

References (21)

1. Heinemann L, Anderson JH Jr. Measurement of insulin absorption and insulin action. Diabetes Technol Ther. 2004;6(5):698-718.
2. Shimoda S, Nishida K, Sakakida M, Konno Y, Ichinose K, Uehara M, Nowak T, Shichiri M. Closed-loop subcutaneous insulin infusion algorithm with a short-acting insulin analog for long-term clinical application of a wearable artificial endocrine pancreas. Front Med Biol Eng. 1997;8(3):197-211.
3. Davis SN, Thompson CJ, Brown MD, Home PD, Alberti KG. A comparison of the pharmacokinetics and metabolic effects of human regular and NPH insulin mixtures. Diabetes Res Clin Pract. 1991;13(1-2):107-17.
4. Kang S, Creagh FM, Peters JR, Brange J, Vølund A, Owens DR. Comparison of subcutaneous soluble human insulin and insulin analogs (Aspb9, Glub27-Aspb10-Aspb28) on meal-related plasmaglucose excursions in type I diabetic subjects. Diabetes Care. 1991;14(7):571-7.
5. Galloway JA, Spradlin CT, Nelson RL, Wentworth SM, Davidson JA, Swarner JL. Factors infuencing the absorption, serum-insulin concentration, and blood-glucose responses after injections of regular insulin and various insulin mixtures. Diabetes Care. 1981;4(3):366-76.
6. Bottermann P, Gyaram H, Wahl K, Ermler R, Lebender A. Insulin concentrations and time-action profiles of three different intermediate-acting insulin preparations in nondiabetic volunteers under glucose-controlled glucose infusion technique. Diabetes Care. 1982;5 Suppl 2:43-52.
7. Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care. 2000;23(5):644-9.
8. Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A, Cordoni C, Costa E, Brunetti P, Bolli GB. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000;49(12):2142-8.
9. Owens DR, Vora JP, Heding LG, Luzio S, Ryder RE, Atiea J, Hayes TM. Human, porcine and bovine ultralente insulin: subcutaneous administration in normal man. Diabet Med. 1986;3(4):326-9.
10. Plank J, Wutte A, Brunner G, Siebenhofer A, Semlitsch B, Sommer R, Hirschberger S, Pieber TR. A direct comparison of insulin analogs aspart and lispro in type 1 diabetic patients. Diabetes Care. 2002;25(11):2053-7.
11. Lehmann ED, Deutsch T. A physiological model of glucose-insulin interaction in type 1 diabetes mellitus. J Biomed Eng. 1992;14(3):235-42.
12. Berger M, Rodbard D. Computer simulation of plasma insulin and glucose dynamics after subcutaneous insulin injection. Diabetes Care. 1989;12(10):725-36.
13. Hedman CA, Lindström T, Arnqvist HJ. Direct comparison of insulin lispro and aspart shows small differences in plasma insulin profiles after subcutaneous injection in type 1 diabetes. Diabetes Care. 2001;24(6):1120-1.
14. von Mach MA, Brinkmann C, Hansen T, Weilemann LS, Beyer J. Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers. Exp Clin Endocrinol Diabetes. 2002;110(8):416-9.
15. Kobayashi T, Sawano S, Itoh T, Kosaka K, Hirayama H, Kasuya Y. The pharmacokinetics of insulin after continuous subcutaneous infusion or bolus subcutaneous injection in diabetic patients. Diabetes. 1983;32(4):331-6.
16. Cernea S, Kidron M, Wohlgelernter J, Modi P, Raz I. Comparison of pharmacokinetic and pharmacodynamic properties of singledose oral insulin spray and subcutaneous insulin injection in healthy subjects using the euglycemic clamp technique. Clin Ther. 2004;26(12):2084-91.
17. Kraegen EW, Chisholm DJ. Insulin responses to varying profiles of subcutaneous insulin infusion: kinetic modelling studies. Diabetologia. 1984;26(3):208-13.
18. Berger M, Cüppers HJ, Hegner H, Jörgens V, Berchtold P. Absorption kinetics and biologic effects of subcutaneously injected insulin preparations. Diabetes Care. 1982;5(2):77-91.
19. Hübinger A, Weber W, Jung W, Wehmeyer K, Gries FA. The pharmacokinetics of two different concentrations of short-acting insulin, intermediate-acting insulin, and an insulin mixture following subcutaneous injection. Clin Investig. 1992;70(7):621-6.
20. Owens DR, Coates PA, Luzio SD, Tinbergen JP, Kurzhals R. Pharmacokinetics of I-125-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the Influence of different subcutaneous injection sites. Diabetes Care. 2000;23(6):813-9.
21. Scholtz HE, Pretorius SG, Wessels DH, Becker RH. Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique. Diabetologia. 2005;48(10):1988-95.